Recent News

The latest news from the governments, medical industry and top online sources.

EMA business hours over holiday period

EMA’s office is closed from 18:00 on Monday 22 December 2025 to 08:30 on Monday 5 January 2026. Outside of working hours and on public holidays, it is possible to call our product emergency hotline on +31(0)88 781 7600. Please note that this is an emergency number and should only be used in the event of […]

Miranda Dini launches GOLD amid industry shifts

New consultancy aims to deliver personalised senior expertise in healthcare communications Miranda Dini has announced the launch of GOLD Strategy & Communications, a global healthcare consultancy designed to provide a personalised, senior-led and agile alternative to the increasingly consolidated agency landscape. The consultancy will operate across key functions, offering specialist services in R&D, clinical, medical […]

Call for expressions of interest for civil society represent…

The European Commission has launched a call for expressions of interest to represent patient and healthcare professional organisations in EMA’s Paediatric Committee (PDCO). Three members and alternates from patient organisations and three members and alternates from healthcare professional organisations will be appointed for a three-year mandate starting on 1 August 2026. The deadline for submission of applications […]

Gobivaz approved across Europe as first Simponi biosimilar

Alvotech and Advanz Pharma secure EC authorisation for treatment of immune-mediated diseases Alvotech and Advanz Pharma have received marketing authorisations from the European Commission for Gobivaz, the first biosimilar to Simponi (golimumab) to be approved in the European Economic Area. The authorisations cover Gobivaz 50 mg/0.5 mL and 100 mg/mL in both pre-filled syringe with […]

EMA partners with healthcare professionals and consumers for…

The campaign was developed jointly with the European Consumer Organisation, the European Association of Hospital Pharmacists, European Association of Nuclear Medicine, the European Paediatric Neurology Society , the European Community Pharmacists and the European Union of General Practitioners, and supported by EMA’s Patients and Consumers Working Party and Healthcare Professionals Working Party. Source/Attributions: This news […]

ProImmune unveils ProVE SL monomers to boost T cell research

New self-loading reagents offer unmatched flexibility for immunologists ProImmune has announced the launch of its ProVE SL Self-Loading MHC Class I Monomers, a new reagent platform designed to enhance antigen-specific CD8+ T cell detection. The Oxford-based life science company says the innovation will offer researchers greater flexibility, speed and coverage across more than 50 HLA […]

Meeting highlights from the Committee for Veterinary Medicin…

CVMP opinions on veterinary medicinal products The Committee adopted by consensus a positive opinion for a marketing authorisation from Zoetis Belgium for Lenivia (izenivetmab), for the reduction of pain associated with osteoarthritis in dogs. The Committee adopted a positive opinion by consensus, recommending the granting of a marketing authorisation for Vaxxitek HVT+IBD+H5 (Avian influenza vaccine (live recombinant)), intended […]

Orexa reports promising results in post-operative recovery t…

Dutch biotech’s ORE-001 shows strong potential to prevent ileus after major surgery Orexa B.V., a life sciences company based in the Netherlands, has announced positive interim results from its ongoing phase 2 trial investigating ORE-001 for the prevention of post-operative ileus (POI) in patients undergoing major abdominal surgery. The multi-centre, double-blind, placebo-controlled study is being […]

Advice on end-of-year submission dates for type I variations…

EMA is advising marketing authorisation holders to submit individual type IA and type IAIN variations and super-groupings for 2025 no later than 21 November 2025. This will enable EMA to acknowledge the validity of the submissions before the Agency’s closure between 23 December 2025 and 5 January 2026, within the 30-day timeframe set out in […]

Xeltis prepares for commercial launch after strong aXess tri…

EU phase 3 data shows major gains in dialysis access performance Xeltis has announced successful results from its aXess EU phase 3 trial, confirming the potential of its restorative vascular access conduit for patients undergoing hemodialysis. The multicentre study met its primary endpoint and showed major improvements compared to standard of care. Conducted across 18 […]